

Supplementary Appendix 3. The details of the data source of studies included in the meta-analysis.

No	Author	Study data source details
1	Ashraf MA ¹	YAS hospital of Tehran University of Medical Sciences
2	Bean D ²	King's College Hospital and Princess Royal University Hospital
3	Benelli G ³	The Hospital of Crema
4	Caraballo C ⁴	Yale Heart Failure Registry
5	Feng Y ⁵	Jinyintan Hospital in Wuhan Shanghai Public Health Clinical Center in Shanghai Tongling People's Hospital in Anhui
6	Feng Z ⁶	Third Xiangya Hospital of Central South University Changsha Public Health Treatment Center First Hospital of Yueyang Junshan People's Hospital of Yueyang, Central Hospital of Shaoyang Central Hospital of Xiangtan, Second Hospital of Changde Central Hospital of Loudi First Affiliated Hospital of University of South China
7	Ip A ⁷	Hackensack Meridian Health network
8	Lee H ⁸	Korea Centers for Disease Control and Prevention
9	Li J ⁹	Central Hospital, Wuhan
10	Mancia G ¹⁰	Database on residents in Lombardy who were beneficiaries of the Regional Health Service
11	Mehra MR ¹¹	International (169 hospitals located in 11 countries in Asia, Europe, and North America)
12	Meng J ¹²	Shenzhen Third People's Hospital*
13	Peng Y ¹³	West Hospital of Wuhan Union Hospital
14	Rentsch CT ¹⁴	Veterans Affairs Birth Cohort
15	Reynolds HR ¹⁵	New York University (NYU) Langone Health
16	Tedeschi S ¹⁶	A prospective cohort from ten Italian hospitals including Policlinico di Sant'Orsola
17	Yan H ¹⁷	Database on citizens of in Gulin town, a suburban area of Ningbo City, in Zhejiang province (14 hospitals)
18	Yang G ¹⁸	Hubei Provincial Hospital of Traditional Chinese Medicine
19	Zeng Z ¹⁹	Hankou Hospital, Wuhan

20	Zhang P ²⁰	Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan First Hospital, Wuhan Third Hospital, Wuhan Seventh Hospital, Wuhan Ninth Hospital, Thunder Mountain Hospital, Huanggang Central Hospital, and the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
----	-----------------------	---

References

1. Ashraf MA, Shokouhi N, Shirali E, et al. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. 2020.
2. Bean D, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. 2020.
3. Benelli G, Buscarini E, Canetta C, et al. SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. 2020.
4. Caraballo C, McCullough M, Fuery M, et al. COVID-19 Infections and Outcomes in a Live Registry of Heart Failure Patients Across an Integrated Health Care System. medRxiv 2020:2020.04.27.20082016.
5. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. American journal of respiratory and critical care medicine 2020.
6. Feng Z, Li J, Yao S, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. 2020.
7. Ip A, Parikh K, Parrillo JE, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. 2020.
8. Lee H-Y, Ahn J, Kang CK, et al. Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. 2020.
9. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol 2020.
10. Mancina G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020.
11. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med 2020.
12. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. 2020;9:757-60.
13. Peng Y, Meng K, Guan H, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. 2020;48:E004-E.
14. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. 2020.
15. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020.
16. Tedeschi S, Giannella M, Bartoletti M, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020.
17. Yan H, Valdes AM, Vijay A, et al. Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zhejiang Province, China. medRxiv 2020:2020.04.24.20077875.

18. Yang G, Tan Z, Zhou L, et al. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. *Hypertension* 2020.
19. Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. 2020.
20. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circulation research* 2020.